CureVac’s (CVAC) “Buy” Rating Reiterated at JMP Securities

CureVac (NASDAQ:CVACGet Rating)‘s stock had its “buy” rating restated by research analysts at JMP Securities in a report released on Thursday, TipRanks reports. They presently have a $37.00 price target on the stock. JMP Securities’ target price would indicate a potential upside of 107.40% from the stock’s previous close.

Separately, Zacks Investment Research raised shares of CureVac from a “hold” rating to a “buy” rating and set a $19.00 price objective on the stock in a research report on Tuesday, May 3rd. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $46.80.

Shares of CVAC stock traded up $0.33 on Thursday, reaching $17.84. 6,085 shares of the company were exchanged, compared to its average volume of 626,113. The company has a 50-day moving average of $17.66 and a 200-day moving average of $24.57. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.63 and a quick ratio of 2.47. CureVac has a one year low of $14.20 and a one year high of $125.66.

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Signaturefd LLC raised its holdings in shares of CureVac by 2,264.5% in the 4th quarter. Signaturefd LLC now owns 733 shares of the company’s stock worth $25,000 after acquiring an additional 702 shares during the last quarter. Vontobel Holding Ltd. increased its stake in CureVac by 3.8% in the 1st quarter. Vontobel Holding Ltd. now owns 19,411 shares of the company’s stock valued at $381,000 after buying an additional 702 shares during the last quarter. California Public Employees Retirement System increased its stake in CureVac by 0.6% in the 4th quarter. California Public Employees Retirement System now owns 120,622 shares of the company’s stock valued at $4,139,000 after buying an additional 735 shares during the last quarter. Advisor Group Holdings Inc. increased its stake in CureVac by 82.7% in the 3rd quarter. Advisor Group Holdings Inc. now owns 1,900 shares of the company’s stock valued at $104,000 after buying an additional 860 shares during the last quarter. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its stake in CureVac by 12.7% in the 1st quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 7,888 shares of the company’s stock valued at $155,000 after buying an additional 886 shares during the last quarter.

About CureVac (Get Rating)

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidate against COVID-19; CV7202, a prophylactic mRNA-based vaccine, which is in Phase 1 clinical trial for rabies virus glycoprotein; vaccine for lassa yellow fever; vaccine for respirational syncytial virus; CV7301, a second-generation lipid nanoparticle flu vaccine; and vaccines for rota, malaria, and universal influenza.

Further Reading

Analyst Recommendations for CureVac (NASDAQ:CVAC)

Receive News & Ratings for CureVac Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CureVac and related companies with MarketBeat.com's FREE daily email newsletter.